Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-19 Sale | 2024-03-21 4:38 pm | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 2,971 | $2.0855 | $6,196 | 85,686 (Direct) | View |
| 2023-12-20 Sale | 2023-12-22 4:10 pm | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 1,990 | $1.3806 | $2,747 | 48,657 (Direct) | View |
| 2023-03-16 Sale | 2023-03-20 6:43 pm | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 516 | $1.9793 | $1,021 | 37,772 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-01-18 Option Award | 2024-01-19 8:41 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 269,000 | $0 | 317,657 (Direct) | View |
| 2023-12-17 Exercise | 2023-12-19 7:58 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 6,875 | $0 | 57,522 (Direct) | View |
| 2023-02-02 Option Award | 2023-02-06 4:47 pm | N/A 2033-02-01 | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 175,000 | $0 | 188,288 (Direct) | View |
| 2022-08-10 Option Award | 2022-08-12 4:59 pm | N/A 2032-08-09 | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 96,250 | $0 | 96,250 (Direct) | View |
Ownership | 2022-03-09 6:06 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | Ogden Christopher See Remarks | 0 | $0 | 89,863 (Direct) | View |